FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic
The FDA has approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults who have tried other antidepressant medicines but have not benefited from them (treatment-resistant depression). Psychiatrists have called this the biggest advancement in treatment for depression in decades, giving patients hope for a cure for their depression even if previous attempts at treatment have not been successful in relieving their symptoms.
Patients with major depressive disorder who, despite trying at least two antidepressant treatments given at adequate doses for an adequate duration in the current episode, have not responded to treatment are considered to have treatment-resistant depression. For information regarding this revolutionary new treatment for depression and to see if you may be eligible please call our office at 440-333-4949. Intakes for Spravato are available at either our Beachwood or Fairview Park offices.
The drug is only available through a restricted distribution system, under a Risk Evaluation and Mitigation Strategy (REMS).
For more information go to https://www.spravato.com